Lack of Efficacy Ends Trial Evaluating Janssen's HIV Vaccine

Lack of Efficacy Ends Trial Evaluating Janssen's HIV Vaccine Candidate

A phase 3 trial evaluating an investigational HIV vaccine regimen for the prevention of HIV-1 infection will be discontinued.

Related Keywords

, Janssen Research Development , Penny Heaton , Global Therapeutic Area Head , Janssen Research ,

© 2025 Vimarsana